RVNC Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own RVNC shares is 260, representing 87.48% of the company's common stock.

NUVEEN ASSET MANAGEMENT, LLC, in the last quarter, reduced its stake in RVNC by -33.98% restricting it's holding to 352.04 thousand shares of worth nearly $1.73M. BANK OF NEW YORK MELLON CORP also lessened -9.14% of the RVNC shares from its portfolio, reducing its holding to 304.56 thousand shares of worth $1.50M. D. E. SHAW & CO., INC. also shunned RVNC shares holding by -27.6% last quarter which brought its holding to 298.11 thousand shares worth $1.47M.

As per its latest 13F filing, GHOST TREE CAPITAL, LLC increased its stake in RVNC by 20% in the last quarter. The institutional holder raised its holding to 450 thousand shares having worth more than $2.21M. HIGHTOWER ADVISORS, LLC also added 9.59% more shares of RVNC to its portfolio, raising its holding to 445.39 thousand shares of worth $2.19M. RENAISSANCE TECHNOLOGIES LLC also increased its RVNC shares holding by 100% which brought its holding to 373.7 thousand shares worth $1.84M.

The insider with the most stakes in RVNC is Foley Mark J , CEO at the company. Additionally, RVNC stock is highly held by CFO Schilke Tobin and President Sjuts Dustin S among others.

Company executives, directors, and other insiders own 8.56% percent of Revance Therapeutics, Inc.'s stock. Within the last six months, there have been 1 transaction(s) in which RVNC insiders have sold stock, totaling 3.91K shares. Insiders that have sold shares include HOLLANDER DAVID, JORDAN ERICA, and MOXIE DWIGHT.

There have been 0 transaction(s) during the past 6-months in which Revance Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 104.95K Revance Therapeutics, Inc. shares are held by insiders, which represents about 8.56% of RVNC stock.

RVNC CEO, Foley Mark J holds the largest portfolio of the company's shares. RVNC shares owned by Foley total nearly 1.02 million.

ASSENAGON ASSET MANAGEMENT S.A. is the largest institutional owner in RVNC which holds 198.85 thousand shares worth $978.32K or 0.23% of the total RVNC shares outstanding followed by ESSEX WOODLANDS MANAGEMENT, INC. with ownership of 457.09 thousand shares representing 0.54% of the RVNC ownership. GHOST TREE CAPITAL, LLC is the third largest stakeholder with 450 thousand shares or 0.53% of the ownership worth more than $2.21M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the RVNC is concerned, it is a stock which is optionable.

Number of RVNC shares short is 4.51M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 104.39M shares of RVNC are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, RVNC has 91.29M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for RVNC is 1.7.